Effect of an immuno-suppresive medication (cyclosporine) on brain tumor patients survival

A Clinical trial to assess the effects of short-term administration of cyclosporine on survival of patients with glioblastoma multiforme tumor surgery

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201512028612N3

Enrollment

Registered

2016-01-22

Start date

2014-07-23

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioblastoma multiform. Malignant neoplasm of brain/unspecified

Interventions

Intervention 1: Infusion of 2.5 mg/kg cyclosporine over first 2 hours post operation and will be continued with the dose of 5mg/kg /day for 72 hours. Intervention 2: control group: routine care of po

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years No history of surgery and/or previous chemoteraphy Confirmed diagnosis of gliobalstoma

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Performance Status (Survival). Timepoint: measured every 2 months after recruitment up to one year. Method of measurement: Karnofsky Performance Status Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farzaneh

Tehran University of Medical Science

ff1353@yahoo.com+98 21 8490 1000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026